| 40.39 0.09 (0.22%) | 08-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.31 | 1-year : | 55.26 |
| Resists | First : | 40.5 | Second : | 47.31 |
| Pivot price | 40.26 |
|||
| Supports | First : | 39.49 | Second : | 38.86 |
| MAs | MA(5) : | 40.38 | MA(20) : | 39.96 |
| MA(100) : | 30.31 |
MA(250) : | 25.67 |
|
| MACD | MACD : | 0.7  |
Signal : | 0.9 |
| %K %D | K(14,3) : | 92.4 |
D(3) : | 92.4 |
| RSI | RSI(14): 78.4 | |||
| 52-week | High : | 40.5 | Low : | 18.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KDNY ] has closed below upper band by 39.2%. Bollinger Bands are 79.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 40.43 - 40.62 | 40.62 - 40.79 |
| Low: | 39.91 - 40.14 | 40.14 - 40.34 |
| Close: | 40.05 - 40.4 | 40.4 - 40.71 |
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Fri, 07 Jul 2023
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire - Investor's Business Daily
Tue, 13 Jun 2023
Chinook Therapeutics CEO says Novartis acquisition will be 'good for patients' - The Business Journals
Mon, 12 Jun 2023
Carson Block’s Latest Short Bet Is Burned by Novartis M&A Deal - Bloomberg.com
Mon, 12 Jun 2023
Vancouver biotech Chinook Therapeutics to be acquired for US$3.2B - Business in Vancouver
Mon, 12 Jun 2023
Chinook Therapeutics Shares Soar on Novartis Purchase - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 6.116e+007 (%) |
| Held by Institutions | 2.1 (%) |
| Shares Short | 3,130 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2809e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 998.1 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 5.85e+006 % |
| Gross Profit (p.s.) | 210.59 |
| Sales Per Share | -84.86 |
| EBITDA (p.s.) | -2.01612e+008 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -174 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -1.4 |
| Price to Book value | 0 |
| Price to Sales | -0.48 |
| Price to Cash Flow | 5.08 |
| Dividend | 0 |
| Forward Dividend | 2.88e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|